Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2060 for Prevention of Arteriovenous Graft Thrombosis in Hemodialysis Patients
2020-002397-27Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Arteriovenous Graft Occlusion and end-stage kidney disease (ESKD) comparing MK-2060 with Placebo (2 arms). Primary endpoint: Time to First Arteriovenous Graft (AVG) Thrombosis Event. Started Aug 2021; status: active.
02
Drugs
MK-2060
03
Conditions
Arteriovenous Graft Occlusionend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2020-002397-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002397-27.